Pharmaceutical companies are appealing a High Court judgement that upheld the National Institute for Health and Clinical Excellence's decision to restrict the use of anti-dementia medicines for NHS patients in the early stages of Alzheimer's disease.
Eisai and Pfizer, which are launching the appeal, say it is based on the need for greater transparency from NICE about the cost-effectiveness model used for these treatments.
Four clinical commissioning groups in Cheshire have appointed a single accountable officer, ahead of a planned merger by 2020.
A teaching hospital that ran up a deficit of more than £100m overstated the income it hoped to receive while significantly increasing staff numbers, a report has revealed.
The ongoing Brexit muddle seems like the rerun of another law, the Health and Social Care Act 2012, being passed with a proposed aim but failing to materialise in any worthwhile form, says Andy Cowper
We are aware that some of our users are experiencing problems accessing hsj.co.uk.
To protect your security as hsj.co.uk upgrades to a new platform, your existing password will no longer work.
Financial penalties are being lifted from high-profile standards including cancer and elective waiting times, so far without attracting much attention. How is this happening? And will it work, asks Rob Findlay
No comments yet